

December 16, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 ("SEBI Listing Regulations") and outcome of board meeting of the Company.

Ref: Composite Scheme of amalgamation amongst Sequent Scientific Limited ("Sequent" or "Company"), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited ("Viyash"), Geninn Life Sciences Private Limited and Sequent Research Limited ("SRL") and their respective shareholders and the creditors ("Scheme").

With reference to and in furtherance of our disclosures in relation to the Scheme dated September 26, 2024, January 21, 2025, May 26, 2025, August 30, 2025, November 18, 2025, November 19, 2025, November 20, 2025, November 22, 2025, November 26, 2025, and November 28, 2025, we wish to inform you that the Company has received a list of eligible shareholders of Viyash in accordance with the Scheme, and Sequent, Viyash and SRL have filed certified copies of the order passed by the Hon'ble National Company Law Tribunal, Hyderabad bench dated November 18, 2025, sanctioning the Scheme, in Form INC-28 with the Registrar of Companies, today, i.e. December 16, 2025.

Accordingly, as per the terms of the Scheme, Part VI of the Scheme shall become effective from today, i.e., **December 16, 2025**, which shall be considered as **Effective Date 2** (*as defined in the Scheme*).

In this regard, the Board of Directors of the Company at its meeting held today i.e., December 16, 2025, has considered and approved the following matters:

1. Allotment of equity shares

Approved the allotment of 18,19,21,827 equity shares of Sequent having face value of Rs. 2 (Rupees Two) each to the shareholders of Viyash as on the Record Date 2 (*i.e., December 8, 2025*), pursuant to the Scheme as per the Share Exchange Ratio 2, which is as follows:

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Share Exchange Ratio 2: 56 (Fifty-Six) equity shares of Sequent of Rs. 2/- each fully paid up for every 100 (One Hundred) equity shares of Viyash of Rs. 10/- each fully paid up.

Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 50,82,25,298 (Rupees Fifty Crore Eighty Two Lakh Twenty Five Thousand Two Hundred and Ninety Eight only) consisting of 25,41,12,649 equity shares of Rs. 2 each to Rs. 87,20,68,952 (Eighty Seven Crore Twenty Lakh Sixty Eight Thousand Nine Hundred and Fifty Two Only) consisting of 43,60,34,476 equity shares of Rs. 2 each. The said equity shares shall rank *pari passu* in all respects with the existing equity shares of the Company.

Equity shares as allotted by Sequent shall also be listed on the BSE Limited and National Stock Exchange of India Limited as provided in the Scheme in due course.

2. Allotment of warrants

Approved allotment of 2,03,41,257 (Two Crore Three Lakhs Forty-One Thousand Two Hundred and Fifty Seven) share warrants of the Company to the warrant holder of Viyash, in terms of the Scheme at an issue price per share warrant of Rs. 181.94 (Rupees One Hundred Eighty One and Ninety Four paise) determined in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 under the Scheme, as per the Warrant Exchange Ratio, which is as follows:

Warrant Exchange Ratio: 56 (Fifty-Six) warrants of Sequent for every 100 (One Hundred) warrants of Viyash.

Sequent has received 25% of the issue price per warrant i.e. Rs. 181.94 per share warrant as upfront payment aggregating to Rs. 92,52,22,075 for allotment of 2,03,41,257 (Two Crore Three Lakhs Forty-One Thousand Two Hundred and Fifty Seven) share warrants of the Company as per the terms of the Scheme.

Each share warrant shall be convertible into 1 (one) equity share of Sequent of Rs. 2 each in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to receipt of balance consideration of Rs. 2,77,56,66,224 (being 75% of the issue price per warrant) from the allottee to exercise conversion option against each such share warrant. The other terms and conditions of the said warrants shall be as per applicable laws.

3. Changes in management

In furtherance of our disclosure dated August 8, 2025, and pursuant to the effectiveness of the Scheme, the board of directors has:

- (a) Approved appointment of Dr. Haribabu Bodepudi (DIN:01119687) as the Managing Director and Group Chief Executive Officer of the Company for a period of 2 consecutive years w.e.f. December 16, 2025, subject to shareholders approval.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

- (b) Approved change in designation of Mr. Rajaram Narayanan (DIN: 02977405) to Wholetime director designated as Chief Executive Officer – Animal Health of the Company for the remaining period of his existing tenure w.e.f. December 16, 2025, subject to shareholders approval.
- (c) Approved appointment of Mr. Srinivas Vasireddy (DIN:09771153) as an Additional Director (Wholetime and Non-Independent) of the Company for a period of 2 consecutive years w.e.f. December 16, 2025, subject to shareholders approval.
- (d) Approved appointment of Mr. Ramakant Singani as Chief Financial Officer and Key Managerial Personnel of the Company w.e.f. January 1, 2026.
- (e) Noted resignation of Mr. Saurav Bhala as Chief Financial Officer and Key Managerial Personnel of the Company w.e.f. January 01, 2026. The Company places on record its deep sense of appreciation for the services rendered by him and for his contributions to the company. A copy of the resignation letter is enclosed as **Annexure 5A**.

Details required as per the terms of the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and applicable provisions of the SEBI Listing Regulations are enclosed as **Annexures 1 to 5A**.

4. Other matters noted pursuant to and consequential to the Scheme

Noted other matters and actions that occurred in connection with the effectiveness of the Scheme, including:

- (a) CA Hull Investments becoming a promoter of Sequent with effect from the Effective Date 2 pursuant to effectiveness of the Scheme and the consequent allotment of equity shares of Sequent to CA Hull, in accordance with and as contemplated under the Scheme;
- (b) Replacement of Clause V of the Memorandum of Association of Sequent regarding the authorised share capital with the following:

“The Authorised Share Capital of the Company is Rs. 8,86,14,70,000 (Rupees Eight Hundred Eighty Six Crore Fourteen Lakh Seventy Thousand) divided into 4,43,07,35,000 (Four Hundred Forty Three Crore Seven Lakh Thirty Five Thousand) equity shares of Rs. 2 (Rupees Two Only) each with power to increase and/ or reduce the capital, to divide the shares in the capital for the time being into several classes and to attach thereto respectively such qualified or special rights or privileges or conditions as may be determined by or in accordance with the regulations of the Company and to vary, or modify or abrogate any such rights, privileges or conditions in such manner as may from the time being be provided by the regulations of the Company and to consolidate or sub-divide the shares and issue shares of higher or lower denominations.”

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | CIN: L99999TS1985PLC196357

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

- (c) Replacement of Article No. 5 of the Articles of Association of the Sequent regarding the authorised share capital shall, with the following:

“The Authorised Share Capital of the Company is Rs. 8,86,14,70,000 (Rupees Eight Hundred Eighty Six Crore Fourteen Lakh Seventy Thousand) divided into 4,43,07,35,000 (Four Hundred Forty Three Crore Seven Lakh Thirty Five Thousand) equity shares of Rs. 2 (Rupees Two Only) each.

The Company has power from time to time to increase or reduce its capital. Any of the said shares and any new shares thereafter to be created may from time to time be divided into shares of several classes in such manner as may be provided hereinafter and the Company may allow and so that the shares of each class may have or confer such preferred or other special rights and privileges as may be issued under such restrictions and conditions whether in regard to dividend, voting, return of capital or otherwise as shall have been assigned thereto by or under the provisions of the Articles of Association but so that the special rights or privileges belonging to holders of any shares issued with preferred or other rights shall not be varied or abrogated or affected except with sanction as is provided for hereafter.”

The brief details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith in Annexure [6].

- (d) Noted the cessation of Sequent Research Limited as a wholly owned subsidiary of the Company pursuant to its amalgamation with the Company under the Scheme, and Appco Pharma LLC becoming a material subsidiary of the Company upon transfer of all assets and liabilities of Viyash into Sequent under the Scheme with effect from the Effective Date 2.

The Board Meeting commenced at 6.00 p.m. and concluded at 6.40 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**

Yoshita Vora
Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure 1

Dr. Haribabu Bodepudi (DIN: 01119687)		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO of the Company with effect from December 16, 2025.
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from December 16, 2025, for a period of 2 consecutive years, as recommended by Nomination and Remuneration Committee and approved by the Board, liable to retire by rotation, subject to approval of shareholders.
c.	Brief Profile (in case of appointment)	Dr. Hari Babu Bodepudi holds a PhD degree in organic chemistry and has over 30 years of industry experience permeating diverse roles in research, manufacturing, quality and operations in both APIs and oral solids. During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan. He was responsible for more than 50 Mylan facilities globally, managing more than 200 APIs and 15000 SKUs of different formulations. He has hands-on experience in global supply chain, regulatory, API R&D, quality and commercial operations.
d.	Disclosure of relationships between directors (in case of appointment of a director)	None
e.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Dr. Haribabu Bodepudi is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure 2

Mr. Rajaram Narayanan (DIN: 02977405)		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Change in designation of Mr. Rajaram Narayanan (DIN: 02977405) as whole time director designated as CEO – Animal Health of the Company with effect from December 16, 2025.
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from December 16, 2025, for the remaining period of his existing tenure as recommended by Nomination and Remuneration Committee and approved by the Board, liable to retire by rotation, subject to approval of shareholders.
c.	Brief Profile (in case of appointment)	Mr. Rajaram Narayanan has over 30 years of experience, during which he has held key leadership roles in global pharmaceutical and consumer product companies. He joined SeQuent in April 2022 as Managing Director & CEO and has led the strategic reshaping of the organization, returning it to profitability and growth. Prior to joining SeQuent, he was the Managing Director and Country Chair of Sanofi in India for nearly 5 years. He began his career with Hindustan Unilever, after completing his education in Engineering and Business Management. At Unilever he held various commercial assignments of increasing responsibility during an 18 year career in India and Asian markets.
d.	Disclosure of relationships between directors (in case of appointment of a director)	None
e.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Rajaram Narayanan is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure 3

Mr. Srinivas Vasireddy (DIN: 09771153)		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as a whole-time director of the Company with effect from December 16, 2025.
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from December 16, 2025, as an Additional Director (Wholetime and Non-Independent) of the Company for a period of 2 consecutive years, as recommended by Nomination and Remuneration Committee and approved by the Board, liable to retire by rotation, subject to approval of shareholders.
c.	Brief Profile (in case of appointment)	Mr. Vasireddy has around 37 years of experience across all aspects of of API Operations. He has expertise in Manufacturing, PPIC, Third-Party Manufacturing, and driving Quality improvements, Compliance, and EHS enhancements. Currently he was associated with Viyash Group and was responsible for overall API operations across all units. Prior to joining Sequent was head of API (Special Projects) in Mylan Laboratories.
d.	Disclosure of relationships between directors (in case of appointment of a director)	None
e.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Srinivas Vasireddy is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure 4

Mr. Ramakant Singani- Chief Financial Officer		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Ramakant Singani as Chief Financial Officer and Key Managerial Personnel of the Company with effect from January 1, 2026.
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from January 1, 2026, as recommended by Nomination and Remuneration Committee and Audit committee and approved by the Board.
c.	Brief Profile (in case of appointment)	<ul style="list-style-type: none"> • 31 years of experience across all aspects of finance including Business Finance, Accounting, Financial planning and analysis, ERP implementation and cost management • Chief Financial Officer of Viyash since September 2021. • Prior to joining Viyash, was Head of GMO Finance at Dr. Reddy's.
d.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure 5

Mr. Saurav Bhala - Chief Financial Officer		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation of Mr. Saurav Bhala as Chief Financial Officer and Key Managerial Personnel of the Company with effect from January 01, 2026.
b.	Date of Appointment/ reappointment/ cessation (as applicable) and term of appointment/reappointment	Resignation with effect from January 01, 2026.
c.	Brief Profile (in case of appointment)	Not Applicable
d.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

To
Mr. Rajaram Narayanan
Managing Director and Chief Executive Officer
Sequent Scientific Ltd

16.12.2025

**Subject: Resignation from my position as Group Chief Financial Officer
effective from 1st Jan'2026**

Dear Rajaram

I wish to formally resign from my position as Group Chief Financial Officer of Sequent Scientific Ltd, effective 1 January 2026, to pursue external professional opportunities. I will serve the required three-month notice period to ensure a seamless transition of responsibilities.

I am deeply grateful to the Board of Directors and the entire Sequent team for their guidance, trust, and support during my tenure. It has been a privilege to contribute to the company's growth journey and work alongside such talented colleagues.

I extend my best wishes to Sequent and all team members for continued success and future achievements.

Thank you once again for the opportunity and support.



SAURAV BHALA
Group Chief Financial Officer
Sequent Scientific Ltd

Annexure 6

Brief details of alteration o the memorandum and articles of association of the Company		
S. No.	Particulars	Details
1.	Alteration of the memorandum of association	<p>Replacement of Clause V of the memorandum of association of the Company with the following:</p> <p><i>"The Authorised Share Capital of the Company is Rs. 8,86,14,70,000 (Rupees Eight Hundred Eighty Six Crore Fourteen Lakh Seventy Thousand) divided into 4,43,07,35,000 (Four Hundred Forty Three Crore Seven Lakh Thirty Five Thousand) equity shares of Rs. 2 (Rupees Two Only) each with power to increase and/ or reduce the capital, to divide the shares in the capital for the time being into several classes and to attach thereto respectively such qualified or special rights or privileges or conditions as may be determined by or in accordance with the regulations of the Company and to vary, or modify or abrogate any such rights, privileges or conditions in such manner as may from the time being be provided by the regulations of the Company and to consolidate or sub-divide the shares and issue shares of higher or lower denominations."</i></p>
2.	Alteration of the articles of association	<p>Replacement of Article No. 5 of the articles of association of the Company with the following:</p> <p><i>"The Authorised Share Capital of the Company is Rs. 8,86,14,70,000 (Rupees Eight Hundred Eighty Six Crore Fourteen Lakh Seventy Thousand) divided into 4,43,07,35,000 (Four Hundred Forty Three Crore Seven Lakh Thirty Five Thousand) equity shares of Rs. 2 (Rupees Two Only) each.</i></p> <p><i>The Company has power from time to time to increase or reduce its capital. Any of the said shares and any news shares thereafter to be created may from time to time be divided into shares of several classes in such manner as may be provided hereinafter and the Company may allow and so that the shares of each class may have or confer such preferred or other special rights and privileges as may be issued under such restrictions and conditions whether in regard to dividend, voting, return of capital or otherwise as shall have been assigned thereto by or under the provisions of the Articles of Association but so that the special rights or privileges belonging to holders of any shares issued with preferred or other rights shall not be varied or abrogated or affected except with sanction as is provided for hereafter."</i></p>

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | CIN: L99999TS1985PLC196357

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in